Russell Investments Group
ZNTL icon

Russell Investments Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Russell Investments Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-150,990
Closed -$175K – 4237
2025
Q2 		$175K Sell
150,990
-1,265
-0.8% -$1.67K ﹤0.01% 2684
2025
Q1 		$242K Buy
152,255
+92,234
+154% +$199K ﹤0.01% 2535
2024
Q4 		$182K Buy
60,021
+37,726
+169% +$124K ﹤0.01% 2562
2024
Q3 		$82K Buy
+22,295
New +$81K ﹤0.01% 2696
2023
Q4 		– Sell
-99,412
Closed -$1.99M – 3319
2023
Q3 		$1.99M Sell
99,412
-6,461
-6% -$164K ﹤0.01% 1545
2023
Q2 		$2.99M Buy
105,873
+50,803
+92% +$1.22M 0.01% 1331
2023
Q1 		$947K Sell
55,070
-18,281
-25% -$370K ﹤0.01% 1996
2022
Q4 		$1.48M Sell
73,351
-6,415
-8% -$138K ﹤0.01% 1769
2022
Q3 		$1.73M Buy
79,766
+1,978
+3% +$54.1K ﹤0.01% 1634
2022
Q2 		$2.18M Buy
77,788
+19,169
+33% +$508K ﹤0.01% 1541
2022
Q1 		$2.7M Sell
58,619
-645
-1% -$34.8K ﹤0.01% 1478
2021
Q4 		$4.98M Buy
59,264
+1,751
+3% +$135K 0.01% 1252
2021
Q3 		$3.83M Buy
57,513
+10,990
+24% +$634K 0.01% 1410
2021
Q2 		$2.47M Buy
46,523
+23,187
+99% +$1.24M ﹤0.01% 1781
2021
Q1 		$1.01M Hold
23,336
– – ﹤0.01% 2240
2020
Q4 		$1.21M Buy
+23,336
New +$1.05M ﹤0.01% 2037

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Russell Investments Group's ZNTL Position: Q3 2025 in Review

Russell Investments Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 150,990 shares — an estimated $175K sold.

Russell Investments Group first reported a position in ZNTL in Q4 2020 and held it in 16 quarters. The position peaked at $4.98M in Q4 2021. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

  • Russell Investments Group reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Russell Investments Group sold 150,990 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $175K.
  • Russell Investments Group first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • Russell Investments Group's Zentalis Pharmaceuticals position peaked at $4.98M in Q4 2021.
  • 99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Russell Investments Group's 13F filing for Q3 2025, filed 13 Nov 2025.